Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT04171726
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Registry
-
NCT04171726
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Unknown status
Technical summary
Registry record NCT04171726. Allocation not applicable; no masking; primary purpose treatment. Start 2019-08-01 (actual); primary completion 2023-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation
- Acronym
- REDOX-TAVI
- Condition
- Aortic Valve Stenosis
- Intervention (Drug)
- Edoxaban
- Lead sponsor
- Erasmus Medical Center
- Collaborator
- Daiichi Sankyo
Record details
- Record id
cardio:ct-nct04171726- Content hash
a3d4825ba31bdcd9a4ac4819fb3bbebcd0007e81eeb5abf7decc074540c907fa